Upstream Bio Past Earnings Performance
Past criteria checks 0/6
Upstream Bio's earnings have been declining at an average annual rate of -101%, while the Biotechs industry saw earnings growing at 19.3% annually. Revenues have been growing at an average rate of 5.8% per year.
Key information
-101.0%
Earnings growth rate
-97.4%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | 5.8% |
| Return on equity | -24.2% |
| Net Margin | -3,153.1% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Upstream Bio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 2 | -70 | 15 | 53 |
| 30 Jun 24 | 2 | -55 | 13 | 45 |
| 31 Mar 24 | 2 | -47 | 12 | 38 |
| 31 Dec 23 | 2 | -38 | 11 | 32 |
| 31 Dec 22 | 1 | -24 | 6 | 19 |
Quality Earnings: UPB is currently unprofitable.
Growing Profit Margin: UPB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if UPB's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare UPB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UPB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: UPB has a negative Return on Equity (-24.21%), as it is currently unprofitable.